MX2018007424A - Proteinas de union al antigeno bispecifico de anti-tl1a/anti-tnf-a y sus usos. - Google Patents
Proteinas de union al antigeno bispecifico de anti-tl1a/anti-tnf-a y sus usos.Info
- Publication number
- MX2018007424A MX2018007424A MX2018007424A MX2018007424A MX2018007424A MX 2018007424 A MX2018007424 A MX 2018007424A MX 2018007424 A MX2018007424 A MX 2018007424A MX 2018007424 A MX2018007424 A MX 2018007424A MX 2018007424 A MX2018007424 A MX 2018007424A
- Authority
- MX
- Mexico
- Prior art keywords
- tl1a
- binding proteins
- antigen binding
- tnf
- bispecific antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
Abstract
La presente invención hace referencia a proteínas de unión al antígeno que se unen a TL1A, inclusive proteínas de unión al antígeno biespecífico (p. ej., anticuerpos) a TL1A y TNF-a. Dichos anticuerpos biespecíficos pueden estar en un formato de inmunoglobulina tetramérica, en el cual un par de cadena pesada-cadena ligera del anticuerpo se dirige al TL1A y el otro a TNF-a. Las proteínas de unión al antígeno biespecífico pueden estar incluidas también en una fusión de lgG-scFv, donde un anticuerpo tetramérico convencional dirigido a un antígeno se fusiona con un par de unidades Fv de cadena simple dirigido al otro. La proteína de unión al antígeno biespecífico se puede incluir también en una fusión de lgG-Fab, en la que una molécula Fab que se une a un antígeno se fusiona con cada cadena pesada de un anticuerpo tetramérico convencional dirigido al otro antígeno. La invención hace referencia también a los usos de las proteínas de unión a anti-TL1A y las proteínas de unión al antígeno de anti-TL1A/anti-TNF-a y las formulaciones farmacéuticas de estas.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562268432P | 2015-12-16 | 2015-12-16 | |
US201662333063P | 2016-05-06 | 2016-05-06 | |
PCT/US2016/052006 WO2017049004A1 (en) | 2015-09-15 | 2016-09-15 | Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof |
PCT/US2016/066722 WO2017106383A1 (en) | 2015-12-16 | 2016-12-14 | Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018007424A true MX2018007424A (es) | 2018-09-21 |
Family
ID=59057540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018007424A MX2018007424A (es) | 2015-12-16 | 2016-12-14 | Proteinas de union al antigeno bispecifico de anti-tl1a/anti-tnf-a y sus usos. |
Country Status (24)
Country | Link |
---|---|
US (2) | US11104745B2 (es) |
EP (1) | EP3390444A1 (es) |
JP (1) | JP7263007B2 (es) |
KR (1) | KR20180099723A (es) |
CN (1) | CN109311971A (es) |
AU (2) | AU2016370659B2 (es) |
BR (1) | BR112018012096A2 (es) |
CA (1) | CA3008267A1 (es) |
CL (3) | CL2018001596A1 (es) |
CO (1) | CO2018007355A2 (es) |
CR (1) | CR20180365A (es) |
EA (1) | EA201891322A1 (es) |
IL (1) | IL259847A (es) |
JO (1) | JO3816B1 (es) |
MA (1) | MA44060A (es) |
MX (1) | MX2018007424A (es) |
PH (1) | PH12018501284A1 (es) |
SG (2) | SG10201912002YA (es) |
TN (1) | TN2019000275A1 (es) |
TW (1) | TWI799368B (es) |
UA (1) | UA124305C2 (es) |
UY (1) | UY37027A (es) |
WO (1) | WO2017106383A1 (es) |
ZA (1) | ZA201904491B (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010062960A2 (en) | 2008-11-26 | 2010-06-03 | Cedars-Sinai Medical Center | METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE |
CA2850549C (en) | 2011-09-30 | 2023-03-14 | Teva Pharmaceuticals Australia Pty Ltd. | Antibodies against tl1a and uses thereof |
UY35148A (es) * | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
CN112870368A (zh) | 2013-03-27 | 2021-06-01 | 西达-赛奈医疗中心 | 通过抑制tl1a的功能和相关信号传导途径来减轻并逆转纤维化和炎症 |
EP3022295A4 (en) | 2013-07-19 | 2017-03-01 | Cedars-Sinai Medical Center | Signature of tl1a (tnfsf15) signaling pathway |
TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
WO2017161342A1 (en) | 2016-03-17 | 2017-09-21 | Cedars-Sinai Medical Center | Methods of diagnosing inflammatory bowel disease through rnaset2 |
EP3532489A4 (en) | 2016-10-26 | 2020-07-08 | Cedars-Sinai Medical Center | ANTI-TL1A NEUTRALIZING MONOCLONAL ANTIBODIES |
TW201904588A (zh) * | 2017-06-25 | 2019-02-01 | 美商西雅圖免疫公司 | 引導及導航控制蛋白質之製造及使用方法 |
EP3456738A1 (en) | 2017-09-19 | 2019-03-20 | Tillotts Pharma Ag | Antibody variants |
EP3735270A1 (en) * | 2018-01-05 | 2020-11-11 | Modernatx, Inc. | Polynucleotides encoding anti-chikungunya virus antibodies |
CN112585165A (zh) | 2018-04-25 | 2021-03-30 | 普罗米修斯生物科学公司 | 优化的抗tl1a抗体 |
CN111909268B (zh) * | 2019-05-07 | 2022-04-19 | 北京天成新脉生物技术有限公司 | 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用 |
EP3969621A4 (en) * | 2019-05-14 | 2023-01-25 | Prometheus Biosciences, Inc. | TL1A PATIENT SELECTION METHODS, SYSTEMS AND DEVICES |
CN113968910A (zh) * | 2019-07-11 | 2022-01-25 | 武汉友芝友生物制药有限公司 | 四价对称双特异性抗体 |
MX2022000726A (es) | 2019-07-19 | 2022-02-10 | Oncoresponse Inc | Anticuerpos inmunomoduladores y metodos de uso de los mismos. |
CN114901311A (zh) | 2019-10-24 | 2022-08-12 | 普罗米修斯生物科学公司 | Tnf样配体1a(tl1a)的人源化抗体及其用途 |
CN113121696A (zh) * | 2019-12-31 | 2021-07-16 | 周易 | Fab改造诱导形成的双特异性抗体及其制备方法和用途 |
KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
JP2023530046A (ja) * | 2020-04-02 | 2023-07-13 | ラ ホヤ インスティテュート フォー イムノロジー | Tnfファミリーのメンバーの二重標的化のための方法および組合せ |
KR20230024904A (ko) * | 2020-05-20 | 2023-02-21 | 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 | Sars-cov-2에 대한 강력한 중화 항체, 그의 생성 및 용도 |
MX2023000949A (es) | 2020-07-23 | 2023-02-22 | Othair Prothena Ltd | Anticuerpos anti-beta-amiloide (abeta). |
EP4200338A1 (en) * | 2020-08-20 | 2023-06-28 | Amgen Inc. | Antigen binding proteins with non-canonical disulfide in fab region |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4603044A (en) | 1983-01-06 | 1986-07-29 | Technology Unlimited, Inc. | Hepatocyte Directed Vesicle delivery system |
DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
JP3202999B2 (ja) | 1991-01-31 | 2001-08-27 | 協和醗酵工業株式会社 | 肝移行性リポソーム製剤 |
US5830877A (en) | 1993-08-26 | 1998-11-03 | The Regents Of The University Of California | Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory |
US7820798B2 (en) | 1994-11-07 | 2010-10-26 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
DE69731289D1 (de) | 1996-03-18 | 2004-11-25 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
DK1500329T3 (da) | 1996-12-03 | 2012-07-09 | Amgen Fremont Inc | Humane antistoffer, der specifikt binder TNF-alfa |
ES2284247T3 (es) | 1998-04-03 | 2007-11-01 | University Of Iowa Research Foundation | Metodos y productos para estimular el sistema inmunitario usando oligonucleotidos y citoquinas inmunoterapeuticos. |
KR101222450B1 (ko) | 1999-03-25 | 2013-01-16 | 애보트 게엠베하 운트 콤파니 카게 | 사람 il-12에 결합하는 사람 항체 및 이의 제조방법 |
US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
EP1210435A1 (en) | 1999-08-04 | 2002-06-05 | Amgen Inc. | Fhm, A NOVEL MEMBER OF THE TNF LIGAND SUPERGENE FAMILY |
AU2003298816C1 (en) | 2002-12-02 | 2010-12-16 | Amgen Fremont, Inc. | Antibodies directed to Tumor Necrosis Factor and uses thereof |
DK1667730T3 (da) | 2003-08-20 | 2013-09-23 | Univ Miami | Sammensætninger og fremgangsmåder til behandling af inflammatorisk lungesygdom |
US10011858B2 (en) | 2005-03-31 | 2018-07-03 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US20110217310A1 (en) | 2007-01-10 | 2011-09-08 | Siegel Richard M | Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology |
EP2220122A2 (en) | 2007-11-13 | 2010-08-25 | Teva Biopharmaceuticals USA, Inc. | Humanized antibodies against tl1a |
PT2235064E (pt) | 2008-01-07 | 2016-03-01 | Amgen Inc | Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática |
JP5522405B2 (ja) | 2008-04-25 | 2014-06-18 | 協和発酵キリン株式会社 | 安定な多価抗体 |
MX2011010169A (es) | 2009-04-07 | 2011-10-11 | Roche Glycart Ag | Anticuerpos biespecificos anti-erbb-1/anti-c-met. |
US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
JO3375B1 (ar) | 2010-11-08 | 2019-03-13 | Regeneron Pharma | أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) |
UY33827A (es) | 2010-12-22 | 2012-07-31 | Abbott Lab | Proteínas de unión a media-inmunoglobulina y sus usos |
UY33826A (es) | 2010-12-22 | 2012-07-31 | Abbott Lab | Proteínas de unión con dominios trivariables y sus usos |
KR20140104344A (ko) | 2011-05-20 | 2014-08-28 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 시크리터리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비시스 | T 세포 매개성 질병의 병증을 개선하기 위한 tl1a-dr3의 상호작용의 차단 및 그것의 항체 |
WO2013041687A1 (en) | 2011-09-23 | 2013-03-28 | Amgen Research (Munich) Gmbh | Bispecific binding molecules for 5t4 and cd3 |
CA2850549C (en) | 2011-09-30 | 2023-03-14 | Teva Pharmaceuticals Australia Pty Ltd. | Antibodies against tl1a and uses thereof |
WO2013177101A2 (en) | 2012-05-22 | 2013-11-28 | Bristol-Myers Squibb Company | Bispecific antibodies and methods of using the same |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
WO2014082179A1 (en) | 2012-11-28 | 2014-06-05 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
PE20151289A1 (es) | 2013-01-02 | 2015-10-05 | Glenmark Pharmaceuticals Sa | Anticuerpos que se unen al tl1a y sus usos |
TW201444867A (zh) | 2013-03-08 | 2014-12-01 | Lilly Co Eli | 抗tnf-抗il-17雙特異性抗體 |
JOP20140087B1 (ar) | 2013-03-13 | 2021-08-17 | Amgen Inc | بروتينات مخصصة ل baff و b7rp1 وإستخداماتها |
US9580486B2 (en) | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
EA201890895A1 (ru) * | 2013-03-15 | 2019-02-28 | Зинджения, Инк. | Мультивалентные и моновалентные мультиспецифические комплексы и их применение |
US20160009824A1 (en) | 2013-03-15 | 2016-01-14 | Merck Patent Gmbh | Tetravalent bispecific antibodies |
UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
SG10201810298VA (en) | 2013-11-13 | 2018-12-28 | Pfizer | Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof |
US20160052006A1 (en) | 2013-11-22 | 2016-02-25 | Sheila S. Pirtle | Spray Bottle |
-
2016
- 2016-09-15 CR CR20180365A patent/CR20180365A/es unknown
- 2016-12-14 EP EP16822583.7A patent/EP3390444A1/en active Pending
- 2016-12-14 JP JP2018531447A patent/JP7263007B2/ja active Active
- 2016-12-14 UA UAA201806971A patent/UA124305C2/uk unknown
- 2016-12-14 WO PCT/US2016/066722 patent/WO2017106383A1/en active Application Filing
- 2016-12-14 SG SG10201912002YA patent/SG10201912002YA/en unknown
- 2016-12-14 AU AU2016370659A patent/AU2016370659B2/en active Active
- 2016-12-14 MA MA044060A patent/MA44060A/fr unknown
- 2016-12-14 EA EA201891322A patent/EA201891322A1/ru unknown
- 2016-12-14 BR BR112018012096-0A patent/BR112018012096A2/pt active Search and Examination
- 2016-12-14 MX MX2018007424A patent/MX2018007424A/es unknown
- 2016-12-14 TN TNP/2019/000275A patent/TN2019000275A1/en unknown
- 2016-12-14 KR KR1020187020093A patent/KR20180099723A/ko not_active Application Discontinuation
- 2016-12-14 CN CN201680082044.0A patent/CN109311971A/zh active Pending
- 2016-12-14 US US16/062,096 patent/US11104745B2/en active Active
- 2016-12-14 CA CA3008267A patent/CA3008267A1/en active Pending
- 2016-12-14 SG SG11201804857WA patent/SG11201804857WA/en unknown
- 2016-12-15 JO JOP/2016/0261A patent/JO3816B1/ar active
- 2016-12-15 UY UY0001037027A patent/UY37027A/es unknown
- 2016-12-16 TW TW105141920A patent/TWI799368B/zh active
-
2018
- 2018-06-06 IL IL259847A patent/IL259847A/en unknown
- 2018-06-14 CL CL2018001596A patent/CL2018001596A1/es unknown
- 2018-06-14 PH PH12018501284A patent/PH12018501284A1/en unknown
- 2018-07-13 CO CONC2018/0007355A patent/CO2018007355A2/es unknown
-
2019
- 2019-07-09 ZA ZA2019/04491A patent/ZA201904491B/en unknown
-
2021
- 2021-05-05 CL CL2021001179A patent/CL2021001179A1/es unknown
- 2021-07-19 US US17/379,968 patent/US20220213226A1/en active Pending
-
2023
- 2023-09-01 CL CL2023002597A patent/CL2023002597A1/es unknown
-
2024
- 2024-01-29 AU AU2024200534A patent/AU2024200534A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018501284A1 (en) | Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof | |
CR20170383A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
MX2020010382A (es) | Anticuerpos biespecificos para pd1 y tim3. | |
WO2018057735A8 (en) | Antibodies for siglec-15 and methods of use thereof | |
WO2013136186A3 (en) | Readily isolated bispecific antibodies with native immunoglobulin format | |
MY189018A (en) | Pd1 and/or lag3 binders | |
EA201391159A1 (ru) | Hla-рестриктированные пептидоспецифические антигенсвязывающие белки | |
CL2011003148A1 (es) | Proteina biespecifica de union a antigeno, que comprende a)2 cadenas ligeras y 2 cadenas pesadas de un anticuerpo que se une especificamente a un antigeno y 2 fragmentos fab, b)dos fragmentos fab adicionales de un anticuerpo que se une especificamente a un segundo antigeno; metodo de preparacion; composicion farmaceutica y uso. | |
MX2022007636A (es) | Anticuerpos biespecificos caninizados y pares de union biespecificos para el tratamiento contra dermatitis atopica. | |
EA201591153A1 (ru) | Антитела, связывающиеся с tl1a, и их применение | |
MX2021015880A (es) | Fragmentos de unión al antígeno cd3 y composiciones que comprenden los mismos. | |
WO2015006337A3 (en) | Compositions and methods for increasing protein half-life in a serum | |
MX2018005831A (es) | Gradientes de ph-sal opuestos para separaciones de proteina mejoradas. | |
BR112014019773A8 (pt) | Ligantes para anticorpo e proteína de fusão fc para cromatografia de afinidade | |
PH12015501650A1 (en) | Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof | |
MX2019003908A (es) | Metodo por multiproteasa. | |
TN2018000212A1 (en) | Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof | |
WO2011130644A3 (en) | Phosphorylated nf45 biomarkers, antibodies and methods of using same | |
EA201892427A1 (ru) | ГУМАНИЗИРОВАННЫЕ АНТИ-FcRn АНТИТЕЛА С СОЗРЕВШЕЙ АФФИННОСТЬЮ | |
MX2022003191A (es) | Terapias de combinacion con anticuerpos entpd2 y cd73. | |
ECSP21028958A (es) | Anticuerpo monoclonal que se une específicamente al antígeno cd20 | |
MX2021012178A (es) | Modificacion de un anticuerpo para la union selectiva al tumor de cd47. | |
MX2017013014A (es) | Anticuerpo dirigido contra proteinas de union a inmunoglobulinas de s. aureus. | |
EA202090581A1 (ru) | Продукты слияния транстиретина и иммуноглобулина | |
MX2022005308A (es) | Epitopo esterico de ceacam1, y anticuerpo anti-ceacam1, o fragmento del mismo, que se une especificamente al mismo. |